What is William Blair's Forecast for ADPT FY2025 Earnings?

Key Points

• William Blair has raised its fiscal year 2025 earnings per share estimate for Adaptive Biotechnologies from ($0.91) to ($0.81), indicating improved expectations for the company.
• Adaptive Biotechnologies reported $49.94 million in revenue for the recent quarter, exceeding analyst expectations, and showed a year-over-year revenue increase of 36.3%.
• Shares of ADPT are currently down 4.9%, trading at $11.92, while the stock has a consensus rating of "Moderate Buy" with a price target of $12.38.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) - Research analysts at William Blair increased their FY2025 earnings estimates for shares of Adaptive Biotechnologies in a research note issued to investors on Wednesday, August 6th. William Blair analyst A. Brackmann now expects that the company will earn ($0.81) per share for the year, up from their previous forecast of ($0.91). The consensus estimate for Adaptive Biotechnologies' current full-year earnings is ($0.92) per share. William Blair also issued estimates for Adaptive Biotechnologies' Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.64) EPS.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.07. The business had revenue of $49.94 million during the quarter, compared to the consensus estimate of $49.40 million. Adaptive Biotechnologies had a negative return on equity of 60.93% and a negative net margin of 59.07%. The company's revenue for the quarter was up 36.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.31) EPS.

Several other equities research analysts have also commented on ADPT. JPMorgan Chase & Co. boosted their price objective on shares of Adaptive Biotechnologies from $10.00 to $14.00 and gave the stock an "overweight" rating in a research report on Wednesday. Piper Sandler upped their price target on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the company an "overweight" rating in a report on Wednesday. Craig Hallum began coverage on shares of Adaptive Biotechnologies in a research report on Wednesday, June 18th. They issued a "buy" rating and a $15.00 price target on the stock. TD Cowen lifted their price objective on Adaptive Biotechnologies from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Morgan Stanley upped their target price on Adaptive Biotechnologies from $7.00 to $9.00 and gave the company an "equal weight" rating in a research note on Monday, May 5th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $12.38.

Adaptive Biotechnologies Stock Down 2.7%

Shares of ADPT traded down $0.34 on Friday, reaching $12.20. The stock had a trading volume of 3,119,103 shares, compared to its average volume of 1,967,475. Adaptive Biotechnologies has a twelve month low of $3.98 and a twelve month high of $12.92. The firm has a market capitalization of $1.86 billion, a PE ratio of -14.88 and a beta of 1.92. The firm has a 50-day moving average of $10.92 and a 200 day moving average of $9.09.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently made changes to their positions in ADPT. Bridgefront Capital LLC bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at about $80,000. Personal CFO Solutions LLC bought a new position in shares of Adaptive Biotechnologies during the first quarter valued at approximately $84,000. Blair William & Co. IL bought a new position in shares of Adaptive Biotechnologies during the first quarter valued at approximately $84,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Adaptive Biotechnologies during the 1st quarter worth approximately $87,000. Finally, Candriam S.C.A. bought a new stake in shares of Adaptive Biotechnologies in the 1st quarter worth approximately $90,000. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.